Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of LTBP-2 (Latent transforming growth factor beta binding protein 2) in preparation of cardiac failure test kit and kit containing LTBP-2

A 1. LTBP-2, heart failure technology, applied in biological testing, material testing products, etc., can solve the problems of neglect of heart failure, single marker or multiple markers of heart failure, etc., to achieve high serum dilution ratio and cost. Low, easy-to-use effects

Inactive Publication Date: 2010-07-21
FUWAI HOSPITAL OF CARDIOVASCULAR DESEASE CHINESE ACAD OF MEDICAL SCI
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0012] Currently, we do not have a single marker or combination of markers to address many of the problems associated with heart failure
Even the BNP markers of heart failure frequently reported in the literature do not meet the requirements of an ideal marker, on the other hand, the role of some existing biomarkers in heart failure has been neglected

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of LTBP-2 (Latent transforming growth factor beta binding protein 2) in preparation of cardiac failure test kit and kit containing LTBP-2
  • Application of LTBP-2 (Latent transforming growth factor beta binding protein 2) in preparation of cardiac failure test kit and kit containing LTBP-2
  • Application of LTBP-2 (Latent transforming growth factor beta binding protein 2) in preparation of cardiac failure test kit and kit containing LTBP-2

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] Example 1: Experiment on the relationship between LTBP-2 and heart failure

[0042] The etiology of right ventricular arrhythmogenic heart disease (ARVC) is still unclear, and the main feature is that the right ventricular myocardium is replaced by fibrofatty tissue, causing repeated ventricular arrhythmias. Our 5 heart failure patients with ARVC mainly showed left ventricular dysfunction, and the pathology confirmed that the left ventricular free wall was replaced by fibrofatty tissue. Each specimen was obtained from the left ventricular free wall of a failing heart after heart transplantation and a non-failing donor heart. Some specimens were immediately frozen and stored in liquid nitrogen for gene chips and real-time PCR, and the rest were fixed in 10% formalin for pathological examination.

[0043] Specific steps:

[0044] 1) Gene chip: Use the 70-mer oligonucleotide chip of CapitalBio to detect multiple genes in the myocardial tissues of ARVC heart failure patie...

Embodiment 2

[0054] Embodiment 2 detects the expression of serum LTBP-2 of end-stage heart failure group and normal group with LTBP-2 kit

[0055] There were 96 cases of end-stage heart failure and 100 cases of healthy controls. The expression of serum LTBP-2 in the end-stage heart failure group was significantly higher than that in the control group, P<0.01, and there was a significant statistical difference.

[0056] ELISA specific procedure: LTBP-2 was assessed by enzyme-linked immunosorbent assay. According to the instructions of the ELISA kit of LTBP-2 (product catalog No. ESBL2196, Ever systems Biology Laboratory Inc.). Set blank wells, standard wells and sample wells to be tested respectively. Add 100 μl of sample diluent to the blank well, add 100 μl of standard substance or test sample to the remaining wells, shake gently to mix, cover or cover the microtiter plate, and react at 37°C for 120 minutes. In order to ensure the validity of the experimental results, a new standard sol...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to View More

Abstract

The invention provides a new application of LTBP2. Through experiments, the invention proves that LTBP2 can be used for testing cardiac failure caused by all types of arrhythmogenic right ventricular cardiomyopathy (ARVC), and vertically and horizontally compares the positions of the biomarkers of LTBP2 in cardiac failure. The method of the invention, which uses blood serum to quickly and accurately test LTBP-2 to estimate end-stage heart diseases has great clinical and generalization values. The expression difference of LTBP2 is significant in cardiac failure caused by ARVC and is increased by 7.7 times. A kit prepared from TBP2 for cardiac failure test has the advantages of high sensitivity and specification and high serum dilution rate; however, the prior art which also uses serological testing has poor sensitivity and the like; compared with traditional method for testing cardiac failure, the invention has the advantages of low cost, high efficiency, convenient use and the like.

Description

technical field [0001] The invention relates to a new application of auxiliary transforming growth factor binding protein 2 (LTBP-2), in particular to an application of auxiliary transforming growth factor binding protein 2 in preparing a detection kit for heart failure. Background technique [0002] TGF-β, originally isolated from murine sarcoma, enhances the transforming and proliferative activity of epidermal growth factor (EGF) on non-neoplastic fibroblasts. Almost every cell in the human body can produce TGF-β. Under physiological conditions, TGF-β can regulate cell proliferation, differentiation, participate in embryonic development, immune regulation and other processes. In many disease states, TGF-β production increases, such as tumors, Fibrotic disease and hereditary hemorrhagic telangiectasia. Studies have shown that tumor cells and their stromal cells produce a large amount of TGF-β, which increases the formation of new blood vessels, suppresses immunity, and pro...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/68
Inventor 魏英杰胡盛寿白媛媛张晓玲张浩郑哲张芃黄洁
Owner FUWAI HOSPITAL OF CARDIOVASCULAR DESEASE CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com